Updated:
Sanara MedTech
Sanara MedTech incorporated in Texas and is headquartered in Fort Worth. Ronald T. Nixon leads the firm as Chairman and CEO.
Sanara MedTech
Sanara MedTech incorporated in Texas and is headquartered in Fort Worth. Ronald T. Nixon leads the firm as Chairman and CEO. The company focuses on advanced wound care and surgical repair, developing and distributing products used in a range of surgical settings. Its primary commercial strategy bypasses the traditional direct-sales model in favor of exclusive distribution agreements with independent sales agencies across the United States. The firm's product portfolio includes biomatrix soft-tissue repair grafts, bone-graft substitutes, and negative-pressure wound therapy systems designed for use in general surgery, orthopedics, and women's health. Sanara's distribution model allows it to scale geographically without the fixed cost of a large employed salesforce; the network covers hospitals and outpatient surgery centers in multiple US regions. The company has acquired or licensed technology to expand its clinical footprint, including products cleared by the FDA for specific surgical indications. In 2023, Sanara launched a strategic partnership with a major hospital network to evaluate its surgical technologies in a multi-site clinical study (per the firm, October 2023). Sanara operates additional business units that extend its reach beyond product sales. TEAM Technologies, a wholly owned subsidiary, provides contract manufacturing and packaging for medical device companies. A separate division, Sanara Ventures, manages investments in early-stage healthcare companies with technologies that supplement the core surgical business. In May 2024, the company disclosed a new investment in a biologics startup working on next-generation skin substitutes, a move consistent with its focus on surgical tissue repair (per public record, May 2024). The firm's structure as a publicly traded operating company with a captive manufacturing arm and a venture-investing subsidiary sets it apart from most wound-care businesses. Each unit feeds the others: the manufacturing subsidiary can support portfolio companies, while Sanara Ventures scouts technologies that could eventually move through the company's existing hospital distribution channel. This design creates an internal pipeline from early-stage innovation to clinical use without relying on external acquirers to commercialize new products.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Fort Worth
Corporate office
Fort Worth, TX, United States
Principals
Ronald T. Nixon
Chairman & CEO
Sector focus
Frequently asked questions
How does Sanara MedTech distribute its products?
Sanara distributes its surgical and wound-care products through a network of independent sales agencies under exclusive agreements rather than employing a direct sales force. This asset-light model gives the company access to over 1,500 US hospitals and surgical centers while controlling fixed costs. The independent agencies typically carry complementary but non-competing products from other manufacturers. Sanara provides clinical training and marketing support to these partners.
What is TEAM Technologies and how does it relate to Sanara's core business?
TEAM Technologies is a wholly owned subsidiary of Sanara MedTech that provides contract manufacturing, assembly, and packaging services to other medical device companies. The subsidiary gives Sanara in-house production capabilities and a separate revenue stream serving external clients. Manufacturing know-how from TEAM can also support companies in which Sanara Ventures invests.
What types of wound-care products does Sanara sell?
Sanara's product portfolio covers three main categories: soft-tissue repair grafts derived from biologic materials, bone-graft substitutes for orthopedic and spinal procedures, and negative-pressure wound therapy systems. These products are used in general surgery, orthopedics, women's health, and chronic wound management. The company has received FDA clearance for specific surgical indications across its product lines.
Is Sanara MedTech a family office or a traditional operating company?
Sanara MedTech is a publicly traded operating company with adjacent investment and manufacturing divisions, not a family office. While it makes venture investments through its Sanara Ventures arm, the firm's primary activity is developing, manufacturing, and distributing surgical-wound-care products. Its investment activity is structured to identify technologies that complement the core surgical-product business.
How does Sanara Ventures source its investment opportunities?
Sanara Ventures targets early-stage healthcare companies working on technologies adjacent to the parent company's surgical-wound-care focus. The corporate venture arm can leverage the clinical relationships Sanara already maintains through its hospital distribution network to evaluate new technologies. Portfolio companies may also gain access to manufacturing support through TEAM Technologies.
Who leads Sanara MedTech and what is his background?
Ronald T. Nixon serves as Chairman and CEO of Sanara MedTech. Under his leadership, the company has pursued a strategy of acquiring and licensing surgical technologies while expanding its independent-distribution network across US hospitals. Nixon oversees the operating company, the TEAM Technologies manufacturing subsidiary, and the Sanara Ventures investment division.
What is Sanara's clinical footprint in US hospitals?
Sanara's products are distributed to over 1,500 hospitals and outpatient surgery centers in multiple US regions through its network of independent sales agencies. The company has also partnered with a major hospital network for a multi-site clinical study evaluating its surgical technologies, per the firm's 2023 disclosures. Exact procedure volumes or market share are not publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: